New lupus drug candidate cenerimod tested in chinese patients
NCT ID NCT07266090
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing an experimental drug called cenerimod in 15 Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants take a 4 mg tablet daily for 12 months while continuing their usual lupus medications. The study focuses on safety, how the body processes the drug, and its effect on immune cells. It does not compare cenerimod to a placebo or other treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cenerimod (an experimental oral drug that may reduce immune cell activity)
What this could lead to
If it works, this could point toward a new treatment option for Chinese patients with moderate-to-severe lupus.
What could go wrong
This is a small, early-phase study with only 15 participants and no placebo group. It primarily looks at safety and drug levels, not whether the drug actually improves lupus symptoms. Results may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 471003, China
-
First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330200, China
-
Jiujiang NO.1 peple's hospital
Jiujiang, Jiangxi, 332000, China
-
Peking Union Medical College Hospital
Beijing, 100010, China
-
The First Affiliated Hospital Of Jinan University
Guangzhou, Guangdong, 510630, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China